5.69
0.92 (19.29%)
Penutupan Terdahulu | 4.77 |
Buka | 5.00 |
Jumlah Dagangan | 514,657,848 |
Purata Dagangan (3B) | 113,347,603 |
Modal Pasaran | 101,815,148,544 |
Harga / Pendapatan (P/E TTM) | 51.73 |
Harga / Pendapatan (P/E Ke hadapan) | 36.36 |
Harga / Jualan (P/S) | 3.69 |
Harga / Buku (P/B) | 3.26 |
Julat 52 Minggu | |
Tarikh Pendapatan | 11 Aug 2025 - 15 Aug 2025 |
Hasil Dividen (DY TTM) | 1.02% |
Margin Keuntungan | 12.12% |
Margin Operasi (TTM) | 13.08% |
EPS Cair (TTM) | 0.110 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 11.10% |
Pertumbuhan Pendapatan Suku Tahunan (YOY) | 139.70% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 22.70% |
Nisbah Semasa (MRQ) | 1.26 |
Aliran Tunai Operasi (OCF TTM) | 6.62 B |
Aliran Tunai Bebas Leveraj (LFCF TTM) | 3.90 B |
Pulangan Atas Aset (ROA TTM) | 5.62% |
Pulangan Atas Ekuiti (ROE TTM) | 11.82% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (HK) | Bercampur | Bercampur |
Biotechnology (Global) | Bercampur | Menurun | |
Stok | SINO BIOPHARM | - | - |
AISkor Stockmoo
Konsensus Penganalisis | 0.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -5.0 |
Purata Bergerak Teknikal | 1.5 |
Osilator Teknikal | 4.0 |
Purata | 0.13 |
Saham Serupa
Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
---|---|---|---|---|
SINO BIOPHARM | 102 B | 1.02% | 51.73 | 3.26 |
WUXI BIO | 115 B | - | 33.47 | 2.41 |
PHARMARON | 47 B | 1.13% | 15.04 | 2.21 |
INNOVENT BIO | 141 B | - | - | 10.22 |
AKESO | 101 B | - | - | 13.96 |
BEIGENE | 221 B | - | - | 7.89 |
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2024, 41.8% of the firm's total revenue comes from its innovative product category, which includes innovative drugs and biosimilar drugs. Sino Biopharm’s biggest revenue segment is oncology medicines, accounting for 37.2% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Large Core |
% Dimiliki oleh Orang Dalam | 48.22% |
% Dimiliki oleh Institusi | 16.62% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |